Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v8-FR
Language French French
Date Updated 2023-09-19 2023-07-21
Drug Identification Number 02248416 02248416
Brand name FASTURTEC FASTURTEC
Common or Proper name FASTURTEC FASTURTEC
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients RASBURICASE RASBURICASE
Strength(s) 1.5MG 1.5MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 3 vials 3 vials
ATC code V03AF V03AF
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2023-05-26 2023-05-26
Actual start date 2023-05-25 2023-05-25
Estimated end date 2023-09-29 2023-09-15
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Health Canada has allowed the temporary importation and distribution of Great Britain –labelled product to manage this shortage. Due to the limited inventory available there will be some order restrictions. Lot No. 3J1011, Expiry Date:28.02.2026, PLGB 04425/0821 Please contact LAVALCS@sanofi.com in case of questions. Health Canada has allowed the temporary importation and distribution of Great Britain –labelled product to manage this shortage. Due to the limited inventory available there will be some order restrictions. Lot No. 3J1011, Expiry Date:28.02.2026, PLGB 04425/0821 Please contact LAVALCS@sanofi.com in case of questions.
Health Canada comments